Latest
Buba Galadima reacts to Shekarau’s defection to PDP
Sen. Malam Ibrahim Shekarau of Kano Central, a senior member of the New Nigeria Peoples Party (NNPP), received compassion from senior member Buba Galadima for defecting to the PDP (PDP).
Shekarau resigned from the NNPP, and Galadima responded by claiming that the majority of his (Shekarau’s) supporters will remain in the organization in an interview with the BBC Hausa service.
He continued, “We had already anticipated this happening. He missed the mark in making this defection, therefore I feel bad for him. Everywhere he defected, he continuously complains about unfair treatment. Despite his recent defection, 90% of his admirers will remain in the NNPP and not follow him, I can assure you.
“I warned you that no party wanted to miss even one vote since Shekarau has many votes and a party can win the presidency with one vote. We didn’t want him to leave, but since he made the decision, we should let him go. Shekarau would be a problem for us even if we win the elections, I can assure you of that.
In the upcoming general elections, he declared that the party would write to INEC to request that Shekarau be replaced as the NNPP’s senatorial candidate for Kano Central.
None of the other presidential contenders, according to Galadima, have even a quarter of the support the NNPP candidate, Senator Rabiu Musa Kwankwaso, has in the north.
-
Football1 week agoXabi Alonso targets Arda Guler as Chelsea prepare €100m transfer bid
-
Football1 week agoFIFA confirms Jay-Jay Okocha holds World Cup record
-
Business7 days agoDangote cuts petrol, diesel prices again to boost affordability, economic activity
-
Aviation1 week agoInside Airport Luggage Theft: Experts warn of rising insider syndicates
-
Politics1 week agoAmuwo Odofin: Umeadi emerges winner of NDC Reps Primary
-
Featured1 week agoPSG edge Arsenal on penalties to retain Champions League crown
-
Football1 week agoChampions League Final: Talking points ahead of Arsenal vs. PSG match
-
Health4 days agoSenate hearing set to review research on COVID-19 vaccines, cancer concerns

